Montelukast, a leukotriene receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma

Archives of Internal Medicine

Volumn 160, Issue 16, 2000, Pages 2481-2488

  Reicin, A ^a   White, R ^a   Weinstein, S F ^a   Finn A F , Jr ^a   Nguyen, H ^a   Peszek, I ^a   Geissler, L ^a   Seidenberg, B C ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LORATADINE; MONTELUKAST;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0034638146     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.16.2481     Document Type: Article

References (45)

1. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma
2. Current estimates from the National Health Interview Survey, 1995
3. Leukotrienes are potent constrictors of human bronchi
4. 4 in humans
5. 4 and to methacholine in patients with asthma and normal controls
6. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma
7. 4 receptor antagonist, in subjects with bronchial asthma
8. Montelukast, a once daily leukotriene receptor antagonist in the treatment of chronic asthma: A multicenter, randomized, double-blind trial
9. 1 receptor antagonist, improves the signs and symptoms of asthma over one year of treatment
10. Montelukast for chronic asthma in 6- to 14-year-old children
11. Montelukast (MK-0476) improves asthma over 6 months of treatment in 6- to 14-year-old patients
12. 1 receptor antagonist, improves asthma outcomes over a 3-month treatment period
13. 4 receptor antagonist, improves the signs and symptoms of asthma with a dose as low as 10 mg once daily
14. 4 receptor antagonist, exhibits a dose-related improvement in the once daily treatment of patients with chronic asthma
15. Antihistamines in the treatment of asthma
16. 1-antagonists justify a reassessment of antihistamines in allergy treatment?
17. The relationship between plasma histamine concentrations and bronchial obstruction to antigen challenge in allergic rhinitis
18. Direct evidence of a role for mast cells in the pathogenesis of antigen-induced bronchoconstriction
19. The use of antihistamines in asthma
20. Treatment of bronchial asthma with terfenadine: A randomized controlled trial
21. 1-receptor antagonist in the treatment of grass pollen sensitive asthma
22. Double-blind multicenter study of cetirizine in grass-pollen-induced asthma
23. Anti-allergic activity of loratadine and terfenadine assessed by nasal challenge
24. 1 antihistamines (cetirizine and loratadine) on histamine release and the bronchial response to histamine in atopic patients
25. Comparison of the effect of loratadine on the airway and skin responses to histamine, methacholine, and allergen in subjects with asthma
26. Effect of a non-sedative antihistamine (loratadine) in moderate asthma
27. Lack of effect of loratadine on moderate to severe asthma
28. Loratadine vs. ketotifen in treatment of seasonal allergies
29. Allergic bronchial asthma treated with loratadine
30. Pharmacologic profile of SKandF 104353, a novel, highly potent and selective peptidoleukotriene antagonist
31. 4 and antigen in vitro
32. Isolated bronchi from asthmatics are hyper-responsive to adenosine, which apparently acts by liberation of leukotrienes and histamine
33. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics
34. Standardization of spirometry
35. Measurement characteristics of two asthma symptom diary scales for use in clinical trials
36. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma
37. Allergic rhinitis and asthma: How important is the link?
38. 1 receptor antagonist in asthmatic airways
39. A dose-response study of the bronchodilator action of azelastine in asthma
40. 1 antagonist, on airway dynamics and responsiveness to inhaled histamine in mild asthma
41. Comparison of the bronchodilatory effects of cetirizine, albuterol, and both together versus placebo in patients with mild-to-moderate asthma
42. Bronchial biopsies in asthma: An ultrastructural, quantitative study and correlation with hyperreactivity
43. Blood eosinophil numbers and activity during 24 hours: Effects of treatment with budesonide and bambuterol
44. Montelukast added to inhaled beclomethasone in treatment of asthma
45. Effects of montelukast (a leukotriene receptor antagonist), loratadine, montelukast+loratadine and placebo in seasonal allergic rhinitis and conjunctivitis